

PHARMACY TIMES

High Risk Medication

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT February 19, 2013

The Centers for Medicare and Medicaid Services (CMS) developed performance and quality measures to help Medicare beneficiaries make informed decisions regarding health and prescription drug plans. As part of this effort, CMS adopted measures for High Risk Medication (HRM) endorsed by the Pharmacy Quality Alliance (PQA) and the National Quality Forum (NQF). The HRM was developed using existing HEDIS measurement "Drugs to be avoided in the elderly". The HRM rate analyzes the percentage of Medicare Part D beneficiaries 65 years or older who have received prescriptions for drugs with a high risk of serious side effects in the elderly.

In order to advance patient safety, IEHP will be identifying members over 65 and currently on one of the medications identified in Table 1. Providers will be receiving a list of these members from IEHP on an ongoing basis. IEHP asks providers to review their member's current drug regimen and safety risk and make any appropriate changes when applicable.

Table 1: Medications identified by CMS to be high risk in the elderly:

Drug Class	HRM Drugs	Safety Concerns	IEHP DualChoice
			Formulary
			Alternative(s)
Acetylcholinesterase	Donepezil (in patients	Orthostatic hypotension or	Memantine
Inhibitor	with syncope)	bradycardia	
Amphetamines	Dextroamphetamine	CNS stimulation	Weight Control: Diet
	Lisdextroamphetamine		& lifestyle
	Diethylpropion		modification
	Methylphenidate		
	Phentermine		Depression:
			mirtazapine, trazodone
Analgesic	Pentazocine	Confusion, hallucination,	Mild Pain:
(includes	Meperidine	delirium, fall, fracture	APAP
combination	Tramadol	Lowers seizure threshold	
medications)	Aspirin > 325 mg/day	GI bleeding/peptic ulcer, edema	Mod-Severe Pain
	Diflunisal	may worsen heart failure	Norco
	Etodolac	_	Percocet
	Fenoprofen		Morphine
	Ketoprofen		

	Meclofenamate		
	Mefenamic acid		
	Nabumetone		
	Naproxen		
	Piroxicam		
	Oxaprozin		
	Sulindac		
	Tolmetin		
	Ketorolac		
	Indomethacin		
	Meloxicam		
	Diclofenac		
Anorexia	Megestrol	Minimal effect on weight;	N/A
	1.23823232	increases risk of thrombotic	
		events and possibly death	
Anti-anxiety	Aspirin/meprobamate	Increased risk for delirium,	Buspirone
(includes	Meprobamate	cognitive impairment,	SSRI, SNRI
combination	Clorazepate	dependence, sedation, falls,	borti, britti
medications)	Chlordiazepoxide	fractures, respiratory depression	
medications)	Diazepam	in COPD, syncope	
	Flurazepam	in COLD, syncope	
	Alprazolam	Older adults have increased	
	Estazolam		
		sensitivity to benzodiazepines	
	Lorazepam	and slower metabolism of long-	
Antidonnessonts	Oxazepam	acting agents	CCDI mintananina
Antidepressants	Paroxetine	Worsen delirium, worsen	SSRI, mirtazepine,
		urinary retention, worsen	buproprion,
	A 1.1.1.1	cognitive impairment	nortriptyline,
	Amitriptyline	Highly anticholinergic - greater	trazodone,
	Clomipramine	risk of dry mouth, confusion,	desipramine, low dose
	Imipramine	constipation, urinary retention;	doxepin
	Trimipramine	orthostatic hypotension	
	Doxepin (>6mg/d)		
Anti-emetics	Scopolamine	Poor efficacy, extrapyramidal	Ondansetron
	Trimethobenzamide	side effects	
	Metoclopramide	Extrapyramidal side effects,	
		tardive dyskinesia	
	Prochlorperazine	Cause or worsen delirium,	
		worsen constipation, cognitive	
		impairment, worsen	
		Parkinson's desease	
	Promethazine	Anticholinergic effects (e.g.,	
		confusion, dry mouth,	
		constipation), delirium,	
		cognitive impairment, worsen	
		Parkinson's disease, reduced	
		clearance in elderly	
		TITUITUTE III CIGOTIJ	1

Antihistamines (includes combination products)	First generation: Brompheniramine Carbinoxamine Chlorpheniramine Clemastine Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Diphenhydramine (oral) Doxylamine Hydroxyzine Promethazine	Highly anticholinergic – greater risk of dry mouth, confusion, constipation, urinary retention; clearance reduced with advanced age, tolerance may develop if used as hypnotic	Cetirizine, loratadine
Antihypertensives	Triprolidine Doxazosin Prazosin Terazosin Clonidine Guanfacine Guanabenz Methyldopa Reserpine (>0.1 mg/d) Nifedipine, shortacting	High risk of orthostatic hypotension, bradycardia, CNS adverse effects Nifedipine has risk of precipitating myocardial ischemia	Thiazides, ACE inhibitors, ARB, beta-blocker, calcium channel blocker
Antiparkinson agents	Benztropine Trihexyphenidyl	Delirium, worsen cognitive impairment, worsen constipation, worsen urinary retention; not recommended to prevent antipsychotic-associated extrapyramidal effects; not very effective for Parkinson's disease	Decrease dose or discontinue
Antiplatelet	Dipyridamole, oral short-acting Ticlopidine Cilostazol	May cause orthostatic hypotension; more effective and safer alternatives available May worsen heart failure	Clopidogrel
Antipsychotics	Thioridazine Mesoridazine Chlorpromazine Perphenazine Clozapine Olanzapine	Lower seizure threshold, CNS side effects, increased extrapyramidal side effects, orthostatic hypotension	Risperidone Quetiapine Aripiprazole
Antispasmodics	Belladonna alkaloids Dicyclomine Hyoscyamine Propantheline Scopolamine Clidinium- chlordiazepoxide	Anticholinergic effects (e.g., confusion, dry mouth, constipation, urinary retention), delirium, questionable efficacy	Chronic Constipation: fiber, fluids, Miralax, lactulose Diarrhea: loperamide
Cardiac Drugs	Amiodarone Dronedarone	QT prolongation, hypo- or hyperthyroidism, pulmonary toxicity	Rate control preferred for atrial fibrillation

	D C ('1' 1	D (1 C 1	1
	Dofetilide	Rate control preferred over	
	Flecanide	rhythm control in elderly	
	Ibutilide		
	Procainamide		
	Propafenone		
	Quinidine		
	Sotalol		
	Digoxin >125	Slow renal clearance may lead	
	mcg/day	to toxicity; higher dosages	
		associated with no additional	
		benefit in heart failure	
	Spironolactone >25	Higher risk of hyperkalemia in	
	mg/day	heart failure	
Diabetic Drugs	Chlorpropamide	Prolonged hypoglycemia, SIADH	Glimepiride, Glipizide
	Glyburide	Prolonged hypoglycemia	*Avoid Glucotrol XL
	Sliding scale insulin	Higher risk of hypoglycemia	due to hypoglycemic
		without improvement in	risk
		hyperglycemia management	
		regardless of care setting	
Hormones	Conjugated estrogens	Evidence of carcinogenic	Hot flash: SSRI,
	Esterified estrogens	potential (breast and	gabapentin, non-drug
	Estropipate	endometrium)	therapy
	Topical and oral	,	
	estrogens	Lack of cardioprotective effect	Bone Density:
	1535-8535	and cognitive protection in	calcium, vitamin D,
		older women	alendronate
			Low-dose intravaginal
			estrogen for
			management of lower
			UTIs, dyspareunia,
			other vaginal
			symptoms
	Growth Hormone	Effect on hody composition is	Avoid unless for
	OTOWIII TIOTIIIOIIC	Effect on body composition is small; associated with edema,	hormone replacement
			_
		arthralgia, gynecomastia,	after pituitary gland removal
		impaired fasting glucose, carpal	iciliovai
	Testosterone	tunnel syndrome Potential for cardiac problems;	Avoid unless indicated
		contraindicated in men with	for moderate to severe
	Methyltestosterone		
	Design 1.1.	prostate cancer	hypogonadism
	Desiccated thyroid	Concern for cardiac effects; safer alternatives available	Levothyroxine
Hypnotics	Amobarbital	High rate of physical	Insomnia: non-
	Butabarbital	dependence, tolerance,	pharmacologic
	Butalbital	delirium, risk of overdose,	therapy, low-dose
	Mephobarbital	(narrow therapeutic window)	trazodone, low-dose
	Pentobarbital	,	doxepin, short-term
	Phenobarbital		use of zolpidem,
	Secobarbital		zaleplon, ramelteon
	Temazepam	Cognitive impairment,	,
	Triazolam	delirium, unsteady gait,	
<u> </u>	11102010111	atilitisii, wildicaaj gait,	<u> </u>

	Diazepam	syncope, falls, accidents,	
	Flurazepam	fractures	
	Quazepam		
	Chloral hydrate	Tolerance occurs within 10	
		days; overdose can occur with	
		only 3 times recommended	
		dose; risk outweighs benefits	
Skeletal Muscle	Carisoprodol	Anticholinergic effects (e.g.,	Baclofen
Relaxants	Chlorzoxazone	confusion, dry mouth,	Tizanidine
	Cyclobenzaprine	constipation, urinary retention),	
	Metaxalone	sedation fractures, delirium,	
	Methocarbamol	cognitive impairment,	
	Orphenadrine	questionable efficacy at doses	
		tolerated in elderly	
Urinary Drugs	Nitrofurantoin	Pulmonary toxicity	Depends on infection
		Inadequate concentration in	
		urine if CrCl <60 ml/min	

Please feel free to contact IEHP Pharmaceutical Services Department at 909-890-2049, if you have any questions.

Sincerely,

Inland Empire Health Plan - Pharmaceutical Services Team